1. Lee, Soo Hyun, Li, Yingying, Kim, Hanbyeol, Park, Kyumin, Lee, Chul-Hwan. . The role of EZH1 and EZH2 in development and cancer. In BMB reports, 55, 595-601. doi:. https://pubmed.ncbi.nlm.nih.gov/36476271/
2. Yamagishi, Makoto, Hori, Makoto, Fujikawa, Dai, Watanabe, Toshiki, Uchimaru, Kaoru. . Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas. In Cell reports, 29, 2321-2337.e7. doi:10.1016/j.celrep.2019.10.083. https://pubmed.ncbi.nlm.nih.gov/31747604/
3. Völkel, Pamela, Bary, Aurélie, Raby, Ludivine, Le Bourhis, Xuefen, Angrand, Pierre-Olivier. 2019. Ezh1 arises from Ezh2 gene duplication but its function is not required for zebrafish development. In Scientific reports, 9, 4319. doi:10.1038/s41598-019-40738-9. https://pubmed.ncbi.nlm.nih.gov/30867490/
4. An, Ran, Li, Yu-Qing, Lin, Yue-Ling, Li, Man-Mei, Liu, Zhong. 2022. EZH1/2 as targets for cancer therapy. In Cancer gene therapy, 30, 221-235. doi:10.1038/s41417-022-00555-1. https://pubmed.ncbi.nlm.nih.gov/36369341/
5. Liu, Peng, Nadeef, Seba, Serag, Maged F, Sassone-Corsi, Paolo, Orlando, Valerio. 2024. PRC2-EZH1 contributes to circadian gene expression by orchestrating chromatin states and RNA polymerase II complex stability. In The EMBO journal, 43, 6052-6075. doi:10.1038/s44318-024-00267-2. https://pubmed.ncbi.nlm.nih.gov/39433902/
6. Yamagishi, Makoto, Kuze, Yuta, Kobayashi, Seiichiro, Suzuki, Yutaka, Uchimaru, Kaoru. 2024. Mechanisms of action and resistance in histone methylation-targeted therapy. In Nature, 627, 221-228. doi:10.1038/s41586-024-07103-x. https://pubmed.ncbi.nlm.nih.gov/38383791/